Literature DB >> 12915484

Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?

Sarah Hutchinson1, Andre Furger, Dorothy Halliday, Daniel P Judge, Andrew Jefferson, Harry C Dietz, Helen Firth, Penny A Handford.   

Abstract

FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78+/-2.2 to 27.3+/-2.3%) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915484     DOI: 10.1093/hmg/ddg241

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  43 in total

1.  Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.

Authors:  Janine Meienberg; Marianne Rohrbach; Stefan Neuenschwander; Katharina Spanaus; Cecilia Giunta; Sira Alonso; Eliane Arnold; Caroline Henggeler; Stephan Regenass; Andrea Patrignani; Silvia Azzarello-Burri; Bernhard Steiner; Anders O H Nygren; Thierry Carrel; Beat Steinmann; Gábor Mátyás
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

Review 2.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

3.  ADAMTSL6β protein rescues fibrillin-1 microfibril disorder in a Marfan syndrome mouse model through the promotion of fibrillin-1 assembly.

Authors:  Masahiro Saito; Misaki Kurokawa; Masahito Oda; Masamitsu Oshima; Ko Tsutsui; Kazutaka Kosaka; Kazuhisa Nakao; Miho Ogawa; Ri-ichiroh Manabe; Naoto Suda; Ganburged Ganjargal; Yasunobu Hada; Toshihide Noguchi; Toshio Teranaka; Kiyotoshi Sekiguchi; Toshiyuki Yoneda; Takashi Tsuji
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

Review 4.  Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

Authors:  Alain Li-Wan-Po; Bart Loeys; Peter Farndon; David Latham; Caroline Bradley
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 5.  FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders.

Authors:  Lynn Y Sakai; Douglas R Keene; Marjolijn Renard; Julie De Backer
Journal:  Gene       Date:  2016-07-18       Impact factor: 3.688

Review 6.  Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.

Authors:  Takeshi Mizuguchi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2006-10-24       Impact factor: 3.172

7.  Determination of the molecular basis of Marfan syndrome: a growth industry.

Authors:  Peter H Byers
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.

Authors:  Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  A new mouse model for marfan syndrome presents phenotypic variability associated with the genetic background and overall levels of Fbn1 expression.

Authors:  Bruno L Lima; Enrico J C Santos; Gustavo R Fernandes; Christian Merkel; Marco R B Mello; Juliana P A Gomes; Marina Soukoyan; Alexandre Kerkis; Silvia M G Massironi; José A Visintin; Lygia V Pereira
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome.

Authors:  Gábor Mátyás; Sira Alonso; Andrea Patrignani; Myriam Marti; Eliane Arnold; István Magyar; Caroline Henggeler; Thierry Carrel; Beat Steinmann; Wolfgang Berger
Journal:  Hum Genet       Date:  2007-05-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.